Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 7 | 2026 | 105 | 1.710 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2019 | 96 | 1.300 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 64 | 1.230 |
Why?
|
| Pulmonary Embolism | 3 | 2019 | 51 | 1.160 |
Why?
|
| Knee Joint | 2 | 2018 | 127 | 1.050 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2018 | 37 | 1.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 101 | 0.950 |
Why?
|
| Medicare | 5 | 2022 | 218 | 0.860 |
Why?
|
| Humans | 43 | 2026 | 32284 | 0.850 |
Why?
|
| Postoperative Complications | 7 | 2022 | 818 | 0.850 |
Why?
|
| Neoplasms | 4 | 2022 | 762 | 0.830 |
Why?
|
| Orthopedics | 2 | 2023 | 91 | 0.820 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 764 | 0.690 |
Why?
|
| Case-Control Studies | 7 | 2022 | 854 | 0.690 |
Why?
|
| Retrospective Studies | 13 | 2024 | 3612 | 0.670 |
Why?
|
| United States | 11 | 2023 | 4077 | 0.630 |
Why?
|
| Osteosarcoma | 2 | 2019 | 10 | 0.630 |
Why?
|
| Aged | 16 | 2022 | 10258 | 0.630 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 520 | 0.620 |
Why?
|
| Osteoporosis | 1 | 2020 | 51 | 0.610 |
Why?
|
| Hemophilia B | 1 | 2019 | 6 | 0.600 |
Why?
|
| Shoulder Joint | 1 | 2022 | 138 | 0.600 |
Why?
|
| Hemophilia A | 1 | 2019 | 22 | 0.590 |
Why?
|
| Sarcoma | 3 | 2018 | 82 | 0.590 |
Why?
|
| Middle Aged | 18 | 2024 | 11847 | 0.580 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 58 | 0.560 |
Why?
|
| Teaching | 1 | 2019 | 60 | 0.560 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 130 | 0.540 |
Why?
|
| Ascorbic Acid | 1 | 2018 | 21 | 0.540 |
Why?
|
| Reimbursement Mechanisms | 1 | 2017 | 12 | 0.530 |
Why?
|
| Musculoskeletal Diseases | 1 | 2018 | 33 | 0.530 |
Why?
|
| Hip Fractures | 1 | 2017 | 26 | 0.520 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 3899 | 0.520 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 183 | 0.510 |
Why?
|
| Nutritional Status | 1 | 2017 | 73 | 0.510 |
Why?
|
| Antioxidants | 1 | 2018 | 122 | 0.500 |
Why?
|
| Patient Readmission | 1 | 2017 | 135 | 0.480 |
Why?
|
| Fractures, Bone | 1 | 2017 | 144 | 0.470 |
Why?
|
| Male | 19 | 2024 | 19447 | 0.470 |
Why?
|
| Spasm | 1 | 2016 | 6 | 0.470 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 7 | 0.470 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 33 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 372 | 0.430 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 489 | 0.420 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 73 | 0.420 |
Why?
|
| Angiotensin I | 1 | 2016 | 237 | 0.410 |
Why?
|
| Peptide Fragments | 1 | 2016 | 415 | 0.380 |
Why?
|
| Vascular Malformations | 1 | 2012 | 11 | 0.370 |
Why?
|
| Female | 17 | 2024 | 19953 | 0.370 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 8 | 0.360 |
Why?
|
| Diphosphonates | 1 | 2012 | 9 | 0.360 |
Why?
|
| Alendronate | 1 | 2012 | 10 | 0.360 |
Why?
|
| Risk Assessment | 1 | 2017 | 1423 | 0.360 |
Why?
|
| Fractures, Stress | 1 | 2012 | 10 | 0.350 |
Why?
|
| Brachytherapy | 1 | 2012 | 29 | 0.350 |
Why?
|
| Femoral Fractures | 1 | 2012 | 44 | 0.340 |
Why?
|
| Catheter Ablation | 1 | 2012 | 113 | 0.340 |
Why?
|
| Cephalosporins | 1 | 2021 | 8 | 0.340 |
Why?
|
| Carbapenems | 1 | 2021 | 7 | 0.340 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 30 | 0.340 |
Why?
|
| Referral and Consultation | 2 | 2026 | 138 | 0.320 |
Why?
|
| Wound Healing | 1 | 2021 | 184 | 0.310 |
Why?
|
| Fasting | 1 | 2020 | 88 | 0.310 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 48 | 0.310 |
Why?
|
| Dyslipidemias | 1 | 2020 | 60 | 0.300 |
Why?
|
| Treatment Outcome | 5 | 2022 | 3409 | 0.280 |
Why?
|
| Regenerative Medicine | 1 | 2021 | 216 | 0.280 |
Why?
|
| Adult | 10 | 2024 | 9262 | 0.270 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 26 | 0.270 |
Why?
|
| Secondary Prevention | 2 | 2020 | 73 | 0.260 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 390 | 0.250 |
Why?
|
| Cardiology Service, Hospital | 1 | 2017 | 19 | 0.250 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 34 | 0.250 |
Why?
|
| Animals | 6 | 2022 | 8197 | 0.240 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 65 | 0.230 |
Why?
|
| Dystonia | 1 | 2015 | 7 | 0.220 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Risk Factors | 3 | 2020 | 3936 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.200 |
Why?
|
| Length of Stay | 2 | 2017 | 321 | 0.200 |
Why?
|
| Reoperation | 2 | 2022 | 247 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Bone Density Conservation Agents | 2 | 2020 | 23 | 0.190 |
Why?
|
| Comorbidity | 3 | 2022 | 563 | 0.190 |
Why?
|
| Hypertension | 1 | 2020 | 983 | 0.190 |
Why?
|
| Obesity | 1 | 2020 | 1111 | 0.190 |
Why?
|
| Tissue Scaffolds | 2 | 2021 | 431 | 0.190 |
Why?
|
| Employment | 1 | 2023 | 45 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1159 | 0.180 |
Why?
|
| Physicians | 1 | 2024 | 163 | 0.180 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 50 | 0.170 |
Why?
|
| Medicaid | 1 | 2022 | 101 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Mice | 3 | 2022 | 2571 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 11 | 0.170 |
Why?
|
| Patient Care Team | 2 | 2017 | 123 | 0.160 |
Why?
|
| Papillomaviridae | 1 | 2020 | 23 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 905 | 0.160 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 52 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 65 | 0.160 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 93 | 0.160 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 77 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1081 | 0.150 |
Why?
|
| Knee Prosthesis | 1 | 2019 | 18 | 0.150 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 109 | 0.150 |
Why?
|
| Osteoblastoma | 1 | 2019 | 1 | 0.150 |
Why?
|
| Prosthesis-Related Infections | 1 | 2019 | 31 | 0.150 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2019 | 2 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2022 | 241 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 38 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 43 | 0.150 |
Why?
|
| Blood Transfusion | 1 | 2019 | 69 | 0.150 |
Why?
|
| Comprehension | 1 | 2019 | 18 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 137 | 0.140 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2018 | 4 | 0.140 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2018 | 6 | 0.140 |
Why?
|
| Sarcoma, Synovial | 1 | 2018 | 6 | 0.140 |
Why?
|
| Neurilemmoma | 1 | 2018 | 17 | 0.140 |
Why?
|
| Gout | 1 | 2018 | 13 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 24 | 0.140 |
Why?
|
| Emotions | 1 | 2019 | 55 | 0.140 |
Why?
|
| Patellofemoral Pain Syndrome | 1 | 2018 | 3 | 0.140 |
Why?
|
| Lymphoma | 1 | 2018 | 37 | 0.140 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 14 | 0.140 |
Why?
|
| Hip | 1 | 2018 | 14 | 0.140 |
Why?
|
| Osteoarthritis, Knee | 1 | 2019 | 71 | 0.140 |
Why?
|
| Knee | 1 | 2018 | 27 | 0.140 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 162 | 0.130 |
Why?
|
| Matched-Pair Analysis | 1 | 2017 | 11 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 11 | 0.130 |
Why?
|
| Chondrosarcoma | 1 | 2017 | 5 | 0.130 |
Why?
|
| Resistance Training | 1 | 2018 | 59 | 0.130 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2018 | 24 | 0.130 |
Why?
|
| Cryptococcosis | 1 | 2017 | 7 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 19 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 40 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2017 | 95 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 106 | 0.130 |
Why?
|
| ROC Curve | 1 | 2017 | 169 | 0.130 |
Why?
|
| Osteomyelitis | 1 | 2017 | 26 | 0.130 |
Why?
|
| Hand | 1 | 2017 | 81 | 0.130 |
Why?
|
| Osteoarthritis | 1 | 2017 | 73 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 455 | 0.120 |
Why?
|
| Bone Density | 1 | 2018 | 169 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2018 | 189 | 0.120 |
Why?
|
| Arthroscopy | 1 | 2018 | 243 | 0.120 |
Why?
|
| Acrospiroma | 1 | 2016 | 4 | 0.120 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 650 | 0.120 |
Why?
|
| Muscle Neoplasms | 1 | 2016 | 8 | 0.120 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 55 | 0.120 |
Why?
|
| Hindlimb | 1 | 2016 | 53 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 93 | 0.110 |
Why?
|
| Logistic Models | 1 | 2017 | 743 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2022 | 458 | 0.110 |
Why?
|
| Reference Values | 1 | 2016 | 238 | 0.110 |
Why?
|
| Fibrosis | 1 | 2016 | 126 | 0.110 |
Why?
|
| Random Allocation | 1 | 2016 | 247 | 0.110 |
Why?
|
| Carcinoma | 1 | 2016 | 92 | 0.110 |
Why?
|
| Adolescent | 4 | 2019 | 3518 | 0.110 |
Why?
|
| Bone Nails | 1 | 2015 | 39 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2016 | 471 | 0.110 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2015 | 40 | 0.110 |
Why?
|
| Bone Plates | 1 | 2015 | 72 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 556 | 0.110 |
Why?
|
| Radius Fractures | 1 | 2015 | 68 | 0.100 |
Why?
|
| Disease Progression | 1 | 2016 | 591 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 544 | 0.100 |
Why?
|
| Joint Instability | 1 | 2015 | 87 | 0.100 |
Why?
|
| Young Adult | 3 | 2019 | 2651 | 0.090 |
Why?
|
| Phlebography | 1 | 2012 | 26 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 970 | 0.090 |
Why?
|
| Veins | 1 | 2012 | 34 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 93 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 12 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2022 | 113 | 0.090 |
Why?
|
| Wound Infection | 1 | 2012 | 11 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 35 | 0.090 |
Why?
|
| Imidazoles | 1 | 2012 | 97 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 108 | 0.090 |
Why?
|
| Epithelium | 1 | 2021 | 22 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2021 | 8 | 0.090 |
Why?
|
| Radiography | 1 | 2012 | 358 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 550 | 0.080 |
Why?
|
| Ketone Bodies | 1 | 2020 | 7 | 0.080 |
Why?
|
| Mutation | 1 | 2022 | 497 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 117 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2021 | 367 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2020 | 256 | 0.070 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2018 | 19 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2018 | 21 | 0.070 |
Why?
|
| Hospitalization | 2 | 2022 | 475 | 0.070 |
Why?
|
| Child | 2 | 2019 | 2432 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2018 | 91 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2022 | 1840 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 1212 | 0.060 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 6 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2017 | 62 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2018 | 411 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2017 | 171 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 77 | 0.060 |
Why?
|
| Range of Motion, Articular | 2 | 2018 | 195 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2018 | 601 | 0.060 |
Why?
|
| Professional Misconduct | 1 | 2024 | 3 | 0.050 |
Why?
|
| Medicine | 1 | 2024 | 36 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 1178 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2022 | 86 | 0.040 |
Why?
|
| Lumbosacral Region | 1 | 2021 | 11 | 0.040 |
Why?
|
| Laminectomy | 1 | 2021 | 12 | 0.040 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 1 | 0.040 |
Why?
|
| Germinal Center | 1 | 2020 | 6 | 0.040 |
Why?
|
| Diskectomy | 1 | 2021 | 15 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 14 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2020 | 12 | 0.040 |
Why?
|
| Spinal Fusion | 1 | 2021 | 50 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 86 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 129 | 0.040 |
Why?
|
| Bone Substitutes | 1 | 2019 | 9 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 70 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2019 | 43 | 0.040 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sclerosis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2019 | 79 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 156 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 228 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 114 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 245 | 0.040 |
Why?
|
| Bone Cements | 1 | 2018 | 9 | 0.040 |
Why?
|
| Curettage | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cell Line | 1 | 2019 | 454 | 0.040 |
Why?
|
| Tibia | 1 | 2018 | 54 | 0.030 |
Why?
|
| Bone Transplantation | 1 | 2018 | 49 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 76 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 79 | 0.030 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2017 | 2 | 0.030 |
Why?
|
| Itraconazole | 1 | 2017 | 5 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 388 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2018 | 136 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 272 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 53 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2017 | 44 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2018 | 72 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 792 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 340 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 131 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 116 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 756 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 880 | 0.030 |
Why?
|
| Fractures, Closed | 1 | 2015 | 9 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 44 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 293 | 0.030 |
Why?
|
| Wrist Joint | 1 | 2015 | 56 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 501 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 241 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2019 | 695 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 410 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 198 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 251 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2238 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 2317 | 0.020 |
Why?
|